<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04500145</url>
  </required_header>
  <id_info>
    <org_study_id>CH-L-072</org_study_id>
    <nct_id>NCT04500145</nct_id>
  </id_info>
  <brief_title>Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase III Study of Comparison Between Simultaneous Integrated Boost (SIB) Intensity-modulated Radiation Therapy (IMRT) Versus Routine IMRT/VMAT in LD-SCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thoracic radiotherapy concurrent with chemotherapy stands for the standard regime for limited&#xD;
      staged small cell lung cancer. Involved node radiation（INF） replaced elective node&#xD;
      irradiation（ENI） as the more popular since several trails compared the two regimes.&#xD;
      simultaneous integrated boost IMRT becomes mature with advancing in IMRT and VMAT. The&#xD;
      investigator hypothesis that SIB-IMRT can confine the dose for organs at risk to reduce the&#xD;
      toxicities compared with routine IMRT in limited disease small-cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients recruited divided into two arms：SIB-IMRT or routine IMRT，in the routine arm，the&#xD;
      prescription dose was 60Gy/2Gy/30f，and in the SIB arm ，60Gy was given to the field of the&#xD;
      tumor and metastatic lymph nodes，50Gy was given to CR lesion and high-risk prevention. The&#xD;
      physical advantages of SIB-IMRT are to reduce the radiation dose of organs that are at risk&#xD;
      in the lungs, esophagus, and heart ensuring the adequate dose for tumor area at the same&#xD;
      time. The investigators are carrying out this trial to compare the efficacy, safety, side&#xD;
      effects, and type of failure of the two radiotherapy techniques, which will provide a new&#xD;
      choice and reliable basis for the future dose-segmentation study of limited-stage small-cell&#xD;
      lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Anticipated">October 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress-free survival</measure>
    <time_frame>2 year</time_frame>
    <description>the rate of patients survival from the treatment to death or progress</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year</time_frame>
    <description>rate of patients survival in 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control rate</measure>
    <time_frame>2 year</time_frame>
    <description>recurrence rate of local field in 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side-effects</measure>
    <time_frame>3-6months after radiation</time_frame>
    <description>the rate of radiation pneumatic、oesophagitis、haematological toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SIB-IMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received radiotherapy using IMRT or VMAT，60Gy is given to the field of tumor and metastatic lymph nodes and 50Gy given to CR lesion and high-risk area.concurrent or sequential with 4-6 circles of chemotherapy of EP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>routine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SIB-IMRT</intervention_name>
    <description>60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time</description>
    <arm_group_label>SIB-IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>routine IMRT</intervention_name>
    <description>patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy</description>
    <arm_group_label>routine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-70 years old,KPS≥80&#xD;
&#xD;
          -  pathological small cell lung cancer&#xD;
&#xD;
          -  staged as limited disease SCLC（contralateral hilar invasion not included）&#xD;
&#xD;
          -  receive radiotherapy concurrent or sequential with chemotherapy，if induction&#xD;
             chemotherapy，got PR or SD&#xD;
&#xD;
          -  no other tumors&#xD;
&#xD;
          -  No serious medical diseases and dysfunction of major organs&#xD;
&#xD;
          -  understand this study，able to complete the treatment，accept the following up and sign&#xD;
             the informed consent&#xD;
&#xD;
          -  Contraception in women of childbearing age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other malignant tumor（historically or simultaneously）curable non-melanoma skin cancer&#xD;
             and cervical carcinoma in situ not included&#xD;
&#xD;
          -  Uncontrolled heart disease or myocardial infarction within 6 months&#xD;
&#xD;
          -  History of mental illness&#xD;
&#xD;
          -  Pregnancy or Lactation&#xD;
&#xD;
          -  uncontrolled diabetes、hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zongmei zhou, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>national cancer hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zongmei zhou, Professor</last_name>
    <phone>86 13801389769</phone>
    <email>zhouzongmei2013@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lei deng, Dr</last_name>
    <phone>86 13683377570</phone>
    <email>dengleipumc@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zongmei zhou, professor</last_name>
      <phone>86 13801389769</phone>
      <email>zhouzongmei2013@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zongmei Zhou</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Limited-stage small-cell lung cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>simultaneous integrated boost</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

